Etanercept Injection Site Reaction

Clelland, Susan; Hunek, Jeffrey R.
October 2005
Dermatology Nursing;Oct2005, Vol. 17 Issue 5, p375
Academic Journal
Case Study
This article presents the case study of a 20-year-old female presented with a history of psoriasis and psoriatic arthritis since childhood. She started treatment with the drug called etanercept. There are certain side effects of this drug. As this drug is administered through injection, reactions can occur at the injection sites. There is an erythematous, slightly indurated plaque on the anterior right thigh. Etanercept is a fusion protein that inhibits the pro-inflammatory cytokine TNF. The duration of these reactions is usually 3 to 5 days. Most injection site reactions (ISR) don't require specific treatment. But, if necessary, symptomatic eruptions and ISRs can be treated with cold compresses, topical corticosteroids, oral antihistamines, or acetaminophen. Discontinuation of etanercept is very rarely indicated.


Related Articles

  • Etanercept.  // Reactions Weekly;3/11/2006, Issue 1092, p14 

    Discusses research being done on the development of multiple sclerosis during treatment with etanercept for severe psoriasis. Reference to a study by S. A. Sukal et al., published in the January 2006 issue of the "Journal of the American Academy of Dermatology"; Dosage of etanercept received by...

  • Etanercept.  // Reactions Weekly;9/16/2006, Issue 1119, p12 

    The article presents a case report involving a 30-year-old woman who developed psoriasis during treatment with the drug etanercept for rheumatoid arthritis. After two months of receiving etanercept along with prednisone, methotrexate and diclofenac, the patient presented with well-demarcated...

  • Ciclosporin/etanercept/methotrexate.  // Reactions Weekly;Aug2015, Vol. 1565 Issue 1, p71 

    The article presents case report of a patient who developed thyroid B-cell lymphoma during treatment with methotrexate, ciclosporin and etanercept.

  • Etanercept.  // Reactions Weekly;11/1/2008, Issue 1226, p11 

    The article describes the case of a 43-year-old man who developed multiple angiokeratomas while receiving etanercept for psoriasis and psoriatic arthritis. He started taking etanercept because he had a relapse despite the successful treatment of his psoriatic arthritis and psoriasis. One the...

  • Infliximab.  // Reactions Weekly;6/17/2006, Issue 1106, p13 

    Presents the case of an elderly man who developed hepatitis after receiving infliximab treatment for psoriasis. Dosage of infliximab received by the patient.

  • Treatment of psoriasis with etanercept: An experience from South Kuwait. Al-Abdulrazzaq, Adel; Zadeh, Valid Bagher; Al-Otaibi, Sultan; Tarrab, Sahar; Najem, Nabeel // Journal of Pakistan Association of Dermatologists;2012, Vol. 22 Issue 2, p136 

    Objective To observe the efficacy and safety profile of etanercept in patients with moderate to severe plaque psoriasis. Patients and methods In this retrospective study, 56 patients were treated with etanercept between May 2005 and May 2008. All patients were screened for tuberculosis. They...

  • Anakinra.  // Reactions Weekly;7/26/2008, Issue 1212, p7 

    A case study involving a 52-year-old woman who developed an interstitial granulomatous drug reaction while receiving anakinra for rheumatoid arthritis is presented. The clinical history of the patient, the physical examination and skin biopsy, as well as the results of the examinations are...

  • Sulfasalazine.  // Reactions Weekly;4/11/2009, Issue 1247/1248, p32 

    The article describes the case of a 50-year-old woman who developed drug rash with eosinophilia and systemic symptoms (DRESS) syndrome while under sulfasalazine treatment regimen for seronegative rheumatoid arthritis. Two weeks after receiving the drug, the patient developed an extensive rash...

  • Medsafe updates datasheets for etanercept, clopidogrel.  // Reactions Weekly;8/22/2009, Issue 1266, p3 

    The article reports on an update to the datasheets made by Medsafe of New Zealand for etanercept (Enbrel) to include uveitis as an uncommon adverse drug reaction (ADR), and for clopidogrel, to include information discouraging concomitant use of CYP2C19. The change follows a review of reports...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics